Trogenix Advances Clinical Development of Potentially Curative Therapies for Aggressive Cancers

Trogenix Ltd (“Trogenix”), a pioneering biotech company dedicated to developing innovative cancer therapies, led by Prof. Steve Pollard, Dr. Ken Macnamara, Dr. Dima Kuzmin, Dr. Juan Manuel Iglesias, Tay Salimullah, and Atif Abbas, MD, has secured £70 million / $95 million in Series A led by IQ Capital with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons, the Brain Tumor Investment Fund, and new investors Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital, as well as undisclosed private investors.

The investment highlights the curative promise of Trogenix’s precision genetic medicines, powered by its Odysseus® platform, which uncovers and targets the shared vulnerabilities of solid tumours. Using a novel approach that delivers potent combination payloads to destroy cancer cells and activate the immune system while sparing healthy tissue, Trogenix is redefining how aggressive cancers are treated.

The investment marks Cancer Research Horizons’ largest to date, underscoring the transformative potential of Trogenix’s breakthrough technology to redefine cancer treatment.

Trogenix is redefining cancer treatment with a dual-action approach that kills cancer cells and reactivates the immune system to prevent recurrence. Its Synthetic Super Enhancers (SSEs), designed using the Odysseus® platform, target diseased cell states to precisely deliver cytotoxic and immune-stimulating payloads, enabling potent, durable, and targeted therapies.  

Trogenix’s lead program in glioblastoma (GBM), one of the most aggressive brain cancers, is set to enter clinical trials in Q1 2026. A follow-on program targets colorectal cancer liver metastases (CRCLM), with additional pipeline developments underway in hepatocellular and non-small cell lung carcinoma.